Long-Acting Injectable Findings: AETC ShareSpot

TargetHIV

Recent study findings on the efficacy of long-acting injectable regimens to treat HIV, in various populations, are summarized in HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine, a September 2021 AETC ShareSpot blog by Dr. Susa Coffey of UCSF. 

While the complexities of various trial results are best read in the context of the blog, the following excerpt merits a highlight:

"Many U.S. clinics currently are starting CAB+RPV programs, so we soon will learn the elements needed to successfully implement long-acting injectable ART in clinics and to support patients in treatment (e.g., monitoring adherence to injection visits, tracking patients who miss appointments, having oral ART options readily available for those who interrupt or stop injectable CAB+RPV, etc.)."

Learn More

We'd like your feedback

Was this page helpful?
I found this page helpful because the content on the page:
Check all that apply
I did not find this page helpful because the content on the page:
Check all that apply
Please include an email address if you would like a response
Please include an email address if you would like a response